Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

Imagem de Miniatura
Arquivos
art_CREPEY_Impact_of_quadrivalent_influenza_vaccines_in_Brazil_a_2020.PDF.pdf (1.25 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
CREPEY, Pascal
BOIRON, Louis
ARAUJO, Rafael Rodrigo
LOPEZ, Juan Guillermo
PETITJEAN, Audrey
Citação
BMC PUBLIC HEALTH, v.20, n.1, article ID 1374, 11p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages. Methods We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty. Results Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis. Conclusions Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective.
Palavras-chave
QIV, Quadrivalent, Public health, Cost-effectiveness, Vaccine, Influenza, Brazil
URI
https://observatorio.fm.usp.br/handle/OPI/37865
Referências
  1. AlemAo MM, 2012, FINANCIAMENTO SUS PA, V2012, P186
  2. Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012
  3. [Anonymous], 2016, CAMP NAC VAC INFL 20
  4. [Anonymous], 2016, GUID EC EV INFL VACC, DOI WHO/IVB/16.05 2016
  5. [Anonymous], 2011, CAMP NAC VAC INFL 20
  6. [Anonymous], 2009, TAX COB PLAN PRIV SA
  7. [Anonymous], 2014, DIR MET DIR AV EC
  8. [Anonymous], 2019, LIST PREC MED
  9. [Anonymous], 2015, INF SAUD
  10. [Anonymous], DEP LOG SAUD EXTR DI
  11. [Anonymous], 2019, INF TECN 21 CAMP NAC, P1
  12. [Anonymous], 2017, 148822017 ISOIEC
  13. Bilcke J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102634
  14. Caini S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174592
  15. Caini S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152310
  16. Cheng PY, 2015, INFLUENZA OTHER RESP, V9, P13, DOI 10.1111/irv.12317
  17. Sartori AMC, 2017, HUM VACC IMMUNOTHER, V13, P1454, DOI 10.1080/21645515.2017.1282588
  18. Crepey P, 2015, INFLUENZA OTHER RESP, V9, P39, DOI 10.1111/irv.12318
  19. de Boer PT, 2017, EXPERT REV PHARM OUT, V17, P249, DOI 10.1080/14737167.2017.1343145
  20. de Boer PT, 2016, VALUE HEALTH, V19, P964, DOI 10.1016/j.jval.2016.05.012
  21. de Mello WA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005095
  22. DiazGranados CA, 2012, VACCINE, V31, P49, DOI 10.1016/j.vaccine.2012.10.084
  23. Geographic and Statistic Brazilian Institute, 2018, PROD INT BRUT
  24. Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
  25. Jamotte A, 2017, HUM VACC IMMUNOTHER, V13, P877, DOI 10.1080/21645515.2016.1256928
  26. Luna EJA, 2018, INFLUENZA B VIRUS CI
  27. Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
  28. Prosser LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022308
  29. R Core Team, 2019, R LANG ENV STAT COMP
  30. Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369
  31. Reed C, 2012, VACCINE, V30, P1993, DOI 10.1016/j.vaccine.2011.12.098
  32. Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413
  33. Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036
  34. Van Bellinghen LA, 2018, BRAZ J INFECT DIS, V22, P1, DOI 10.1016/j.bjid.2017.11.004
  35. WHO FluNet, GLOB INFL SURV RESP

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03